Cleerly

Cleerly represents the 2026 benchmark for preventative cardiology, utilizing sophisticated deep learning algorithms to perform comprehensive Coronary Computed Tomography Angiography (CCTA) analysis. Unlike traditional stress tests that measure ischemia (blood flow limitation), Cleerly's architecture focuses on the underlying cause: coronary artery disease (CAD) and specific plaque types. The system identifies, characterizes, and quantifies plaque—specifically low-density non-calcified plaque (LD-NCP), which is the primary predictor of future heart attacks. By 2026, Cleerly's position has matured into a standard-of-care tool within integrated health systems, moving from reactive diagnostics to a proactive, data-driven wellness model. The technical engine automates the tedious vessel segmentation and plaque labeling processes, reducing variability and providing clinicians with a 3D digital twin of a patient’s coronary anatomy. This allows for precision treatment paths based on actual disease volume rather than symptomatic response. Its market position is solidified by massive clinical validation and FDA clearances, making it an essential platform for value-based care organizations aiming to reduce cardiovascular events and associated costs.